

Wissenschaftliche Studien-Ergebnisse*

		ALPHA-LIPON	BOSWELLIA	CURCUMIN	GREEN TEA	RESVERATROL			ALPHA-LIPON	BOSWELLIA	CURCUMIN	GREEN TEA	RESVERATROL
1 = unterstützend								1 = unterstützend					
2 = Gut								2 = Gut					
3 = Sehr Gut								3 = Sehr Gut					
4 = Ausgezeichnet								4 = Ausgezeichnet					
01	Abnehmen (Übergewicht)	3	1	3	3	4	50	Hämorrhoiden	1	1	1	1	1
02	ADHS (Hyperaktivität)	1	1	3	1	1	51	Hashimoto Thyreoiditis	2	1	3	2	2
03	Adipositas (Fettleibigkeit)	3	1	3	3	4	52	Hauterkrankungen (Dermatitis)	1	1	3	1	2
04	AIDS	3	1	3	1	1	53	Hepatitis (alle Typen)	2	2	3	1	1
05	Akne	1	1	1	2	1	54	Herzerkrankungen	3	1	2	1	3
06	Alkoholvergiftung	3	1	2	2	2	55	Hormonstörungen	2	1	2	1	1
07	Allergien Heuschnupfen	1	1	2	1	2	56	Immunsystem geschwächt	3	2	3	2	2
08	Alzheimer Erkrankung Demenz	2	1	3	1	2	57	Karies	1	1	3	2	2
09	Amenorrhoe (Ausbleiben d. Menstruation)	2	1	1	1	1	58	Konzentrationsprobleme	2	2	2	1	2
10	Anämie	2	1	1	1	2	59	Krampfadern (Varizen)	2	2	3	2	2
11	Arteriosklerose	1	1	1	1	2	60	Krebs (Allgemein)	3	3	4	2	3
12	Arthritis	2	2	4	1	1	61	Leberentgiftung	3	2	3	2	2
13	Arthrose	2	2	4	1	1	62	Lebererkrankungen	3	2	3	1	2
14	Asthma	1	1	1	1	1	63	Lungenerkrankungen	2	1	2	1	2
15	Augenerkrankungen	3	1	2	1	1	64	Lymphknotenkrankungen	3	1	3	1	2
16	Bauchspeicheldrüsenkrebs	2	3	4	2	3	65	Magenschleimhautentzündung (Gastritis)	1	1	1	1	1
17	Bindehautentzündung (Konjunktivitis)	2	1	1	1	1	66	Magersucht	1	1	1	1	1
18	Blasenentzündung (Cystitis)	2	2	1	1	1	67	Migräne	1	1	1	1	1
19	Bluthochdruck (Hypertonie)	3	1	2	2	2	68	Milz: Anregung und Entgiftung	2	1	3	1	2
20	Blutkrebs Leukämie	3	3	4	3	3	69	Mittelohrentzündung (Otitis Media)	1	1	1	1	1
21	Bronchialkarzinom	3	3	4	1	3	70	Multiple Sklerose (MS)	2	1	3	1	2
22	Brustkrebs Mammakarzinom	3	3	4	2	3	71	Neurodermitis	1	1	3	1	2
23	Bulimie	1	1	1	1	1	72	Niedriger Blutdruck (Hypotonie)	2	1	1	1	2
24	Burn Out Syndrom	2	1	1	1	1	73	Nierenerkrankungen	2	1	3	1	2
25	Chemotherapie Unterstützung	1	1	4	1	1	74	Osteoporose	2	1	1	1	2
26	Cholesterin zu hoch	2	1	2	4	2	75	Parkinson	1	1	3	1	2
27	Colitis ulcerosa	2	2	2	1	2	76	Pilzinfektionen (Mykosen)	2	1	3	3	1
28	Darm-Gesunderhaltung	2	2	3	1	2	77	Prämenstruelles Syndrom (PMS)	1	1	1	2	1
29	Depressionen	2	1	1	1	1	78	Prostataerkrankungen	2	1	3	1	2
30	Diabetes mellitus Typ 1	3	3	3	2	3	79	Psoriasis	2	1	3	1	1
31	Diabetes mellitus Typ 2	3	3	3	2	3	80	Reflux Oesophagitis	1	1	2	1	1
32	Dickdarmentzündung u. -probleme	2	2	3	1	2	81	Rekonvaleszenz (nach schweren Krankheiten)	2	2	2	2	3
33	Divertikulitis u. Divertikulose Darm	2	2	2	1	2	82	Rheuma rheumatische Beschwerden	2	2	3	1	2
34	Dünndarmentzündung u. -probleme	2	2	2	1	2	83	Schilddrüsenüberfunktion (Hyperthyreose)	2	1	3	1	1
35	Durchblutungsstörungen	2	1	1	1	2	84	Schilddrüsenunterfunktion (Hypothyreose)	2	1	3	1	1
36	Durchfall (akute Diarrhoe)	1	1	1	1	1	85	Schlafstörungen körperliche Ursachen	1	1	1	1	1
37	Durchfall (chronische Diarrhoe)	1	1	1	1	1	86	Schlafstörungen psychische Ursachen	1	1	1	1	1
38	Eisenmangel	2	1	4	1	1	87	Schlaganfall	2	3	1	2	2
39	Entzündungen	2	2	1	2	2	88	Schnupfen	1	1	1	1	1
40	Erektionsstörung schwache Libido	2	1	1	1	1	89	Stoffwechselprobleme	3	1	1	3	2
41	Erkältung	1	1	1	1	1	90	Strahlentherapie bei Krebs Unterstützung	3	1	4	1	1
42	Fieber	1	1	1	1	1	91	Thrombose	2	2	3	2	2
43	Fructoseintoleranz			1	1		92	Tinnitus Hörsturz	2	1	1	1	2
44	Gallensteine (Cholelithiasis)	1	1	1	1	1	93	Toxine Schadstoffbelastungen	3	1	1	3	2
45	Gastritis	1	1	1	1	1	94	Untergewicht	2	1	1	1	2
46	Gedächtnisstörungen	3	1	3	2	3	95	Verstopfung (Obstipation)	1	1	1	1	1
47	Gehirn Kopfbereich	3	1	3	1	1	96	Wassereinlagerungen	2	1	3	2	2
48	Gicht	2	1	1	2	1	97	Wechseljahresbeschwerden	3	1	2	1	3
49	Glutenintoleranz			1	1		98	Zahnfleischentzündungen	2	1	1	2	2

*) Quellenverzeichnis auf den Folgeseiten 12-15





Quellennachweise

Alpha-Liponsäure:

- Androne L, Gavan NA, Veresiu IA, Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. *In Vivo*. 2000;14(2):327-330.
- Beitner H. Randomized, placebo controlled, double-blind study on the clinical efficacy of a cream containing 5% alpha-lipoic acid related to photoaging of facial skin. *Br J Dermatol*. 2003;149:841-9.
- Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. *Med Klin*. 1999;94 Suppl 3:84-89.
- Clark WM, Rinker LG, Lessov NS, Lowery SL, Cipolla MJ. Efficacy of antioxidant therapies in transient focal ischemia in mice. *Stroke*. 2001;32(4):1000-1004.
- Faust A, Burkart V, Ulrich H, et al. Effect of lipoic acid on cyclophosphamide-induced diabetes and insulinitis in non-obese diabetic mice. *Int J Immunopharmacol*. 1994;16:61-66.
- Head KA. Natural therapies for ocular disorders, part two: cataracts and glaucoma. *Altern Med Rev*. 2001;6(2):141-166.
- Hruby K, Csomos G, Fuhrmann M, Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. *Hum Exp Toxicol*. 1983;2(2):183-195.
- Ibrahimspasic K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment. *Med Arh*. 2013; 67(1):7-9.
- Lynch MA. Lipoic acid confers protection against oxidative injury in non-neuronal and neuronal tissue. *Nutr Neurosci*. 2001;4(6):419-438.
- Melhem MF, Craven PA, Derubertis FR. Effects of dietary supplementation of alpha-lipoic acid on early glomerular injury in diabetes mellitus. *J Am Soc Nephrol*. 2001;12:124-133.
- Melhem MF, Craven PA, Liachenko J, et al. Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. *J Am Soc Nephrol*. 2002;13:108-116.
- Melmed: Williams Textbook of Endocrinology, 12th ed. Philadelphia, PA: Saunders, An Imprint of Elsevier; 2011.
- Mitkov MD, Aleksandrova IY, Orbetzova MM. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. *Folia Med (Plovdiv)*. 2013; 55(1):55-63. Monograph: Alpha-Lipoic Acid. *Altern Med Rev*. 1998;3(4):308-311.
- Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. *Diabetes Care*. 1995;18:1160-1167.
- Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. *Nutrition*. 2001;17(10):888-895.
- Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. *Free Radic Biol Med*. 1997;22:359-378.
- Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. *Free Rad Bio Med*. 1995;19(2):227-250.
- Panigrahi M, Sadguna Y, Shivakumar BR, Kolluri SV, Roy S, Packer L, Ravindranath V. Alpha-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats. *Brain Res*. 1996;717(1-2):184-188.
- Rakel D. *Rakel Integrative Medicine*, 3rd ed. Philadelphia, PA: Saunders, An Imprint of Elsevier; 2012.
- Segermann J, Hotze A, Ulrich H, et al. Effect of alpha-lipoic acid on the peripheral conversion of thyroxine to triiodothyronine and on serum lipid-, protein- and glucose levels. *Arzneimittelforschung*. 1991;41:1294-1298.
- Xu J, Gao H, Song L, et al. Flaxseed oil and alpha-lipoic acid combination ameliorates hepatic oxidative stress and lipid accumulation in comparison to lard. *Lipids Health Dis*. 2013; 12:58.
- Yoo TH, Lee JH, Chun HS, Chi SG. a-Lipoic acid prevents p53 degradation in colon cancer cells by blocking NF-kB induction of RPS6KA4. *Anticancer Drugs*. 2013; 24(6):555-65.
- Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. *Diabetes Care*. 2006;29:2365-70.
- Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. *Diabetes*. 1997;46 (suppl 2):S62-66.
- Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. *Exp Clin Endocrinol Diabetes*. 1999; 107:421-430.

Boswellia:

1. Safayhi, H., et al., Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. *J Pharmacol*.

Exp. Ther. 261 (1992) 1143 - 1146.

2. Park, Y. S., et al., Acetyl-11-keto-beta-boswellic acids (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the cellular-signal regulated kinase 1 and 2. *Eicosanoid Congress Boston* (1999) 118.
3. Bertsche, T., Effekte polycyclischer Triterpene aus *Boswellia spec.* auf Mitogen-aktivierte Kinasen in neutrophilen Granulozyten und Glioblastoma-T98G-Zellen. *Diss. Universität Tübingen* 2001.
4. Wang, L.-G., et al., Determination of DNA topoisomerase II activity from L1210 cells – a target for screening antitumor agents. *Acta Pharmacol. Sinica* 12 (1991) 108 - 114.
5. Hoernlein, R. F., et al., Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. *J. Pharmacol. Exp. Ther.* 288 (1999) 613 - 619.
6. Safayhi, H., et al., Inhibition by boswellic acids of human leukocyte elastase. *J. Pharmacol. Exp. Ther.* 281 (1997) 460 - 463.
7. Wagner, H., et al., Pflanzeninhaltsstoffe mit Wirkung auf das Komplementsystem. *Z. Phytother.* 8 (1987) 148 - 149.
8. Boden, S. E., et al., Stimulation of leukotriene synthesis in intact polymorphonuclear cells by the 5-lipoxygenase inhibitor 3-oxo-tirucallic acid. *Molecul. Pharmacol.* 60 (2001) 267 - 273.
9. Etzel, R., Special extract of *Boswellia serrata* (H15) in the treatment of rheumatoid arthritis. *Phytomed.* 3 (1996) 91 - 94.
10. Sander, O., et al., Is H15 (resin extract of *Boswellia serrata* incense) a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study. *Z. Rheumatol.* 57 (1998) 11 - 16.
11. Gupta, I., et al., Effects of *Boswellia serrata* gum resin in patients with ulcerative colitis. *Eur. J. Med. Res.* 2 (1997) 3743.
12. Gupta, I., et al., Effects of *Boswellia serrata* gum resin in patients with chronic colitis. *Planta Med.* 67 (2001) 391 - 395.
13. Gerhard, H., et al., Therapie des aktiven Morbus Crohn mit *Boswellia serrata* Extrakt H15. *Z. Gastroenterol.* 39 (2001) 11 - 17.
14. Gupta, I., et al., Effects of *Boswellia serrata* gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. *Eur. J. Med. Res.* 3 (1998) 511 - 514.
15. Heldt, M. R., et al., Boswellic acids exhibit cytotoxic effects on brain tumor cells independent of 5-lipoxygenase inhibition. *Naunyn Schmeddeberg's Arch. Pharmacol.* (1997) 355.
16. Weller, M., et al., Chemotherapie maligner Gliome. *Nervenheilkunde* 19 (2000) 116 - 120.
17. Streffer, J. R., et al., Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. *Neurology* 56 (2001) 1219 - 1221.
18. EMEA, Committee for Orphan Medicinal Products, Public summary of positive opinion for orphan designation of *Boswellia serrata* resin extract for the treatment of peritumoral oedema derived from brain tumors. *EMEA/COMP/2247/02*, London, 11. Dezember 2002.

Curcumin:

1. Frantz S. Drug discovery: playing dirty. *Nature*. 2005;437(7061):942-943. doi: 10.1038/437942a. [PubMed] [Cross Ref]
2. Mencher SK, Wang LG. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) *BMC Clin Pharmacol*. 2005;5(1):3. doi: 10.1186/1472-6904-5-3. [PMC free article] [PubMed] [Cross Ref]
3. Vogel A, Pelletier J. Examen chimique de la racine de Curcuma. *J Pharm*. 1815;1:289-300.
4. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. *Clin Exp Pharmacol Physiol*. 2012;39(3):283-299. doi: 10.1111/j.1440-1681.2011.05648.x. [PMC free article] [PubMed] [Cross Ref]
5. Schraufstatter E, Bernth H. Antibacterial action of curcumin and related compounds. *Nature*. 1949;164(4167):456. doi: 10.1038/164456a0. [PubMed] [Cross Ref]
6. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. *Trends Pharmacol Sci*. 2009;30(2):85-94. doi: 10.1016/j.tips.2008.11.002. [PubMed] [Cross Ref]
- Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int J Biochem Cell Biol*. 2009;41(1):40-59. doi: 10.1016/j.jbiocel.2008.06.010. [PMC free article] [PubMed] [Cross Ref]
8. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, et al. Multitargeting by curcumin as revealed by molecular interaction studies. *Nat Prod Res*. 2011;28(12):1937-1955. doi: 10.1039/c1np00051a. [PMC free article] [PubMed] [Cross Ref]
9. Loeber CC. *De curcuma officinarum*. *diss Inaug Halae*. 1748.
10. Oppenheimer A. Turmeric (curcumin) in biliary diseases. *Lancet*. 1937;229:619-621. doi: 10.1016/S0140-6736(00)98193-5. [Cross Ref]
11. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. *Cancer Chemother Pharmacol*. 2011;68(1):157-164. doi: 10.1007/s00280-010-1470-2. [PubMed] [Cross Ref]
12. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clin Cancer Res*. 2008;14(14):4491-4499. doi: 10.1158/1078-0432.CCR-08-0024. [PubMed] [Cross Ref]
13. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. *Clin Cancer Res*. 2001;7(7):1894-1900. [PubMed]
14. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. *Clin Cancer Res*. 2004;10(20):6847-6854. doi: 10.1158/1078-0432.CCR-04-0744. [PubMed] [Cross Ref]
15. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. *Cancer Epidemiol Biomarkers Prev*. 2005;14(1):120-125. [PubMed]
16. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. *Clin Gastroenterol Hepatol*. 2006;4(8):1035-1038. doi: 10.1016/j.cgh.2006.03.020. [PubMed] [Cross Ref]
17. Carroll RE, Banya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. *Cancer Prev Res (Phila)* 2011;4(3):354-364. doi: 10.1158/1940-6207.CAPR-10-0098. [PMC free article] [PubMed] [Cross Ref]
18. He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. *Cancer Investig*. 2011;29(3):208-213. doi: 10.3109/07357907.2010.550592. [PubMed] [Cross Ref]
19. Durgaprasad S, Pai CG, Vasanthkumar, Alvres JF, Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. *Indian J Med Res*. 2005;122(4):315-318. [PubMed]
20. Epeibaum R, Schaffer M, Vizeb B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. *Nutr Cancer*. 2010;62(8):1137-1141. doi: 10.1080/01635581.2010.513802. [PubMed] [Cross Ref]
21. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. *Cancer Biol Ther*. 2010;9(1):8-14. doi: 10.4161/cbt.9.1.10392. [PubMed] [Cross Ref]
22. Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. *Prostate*. 2010;70(10):1127-1133. doi: 10.1002/pros.21147. [PubMed] [Cross Ref]
23. Golombick T, Diamond TH, Badmaev V, Manoharan A, Ramakrishna R. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance—its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. *Clin Cancer Res*. 2009;15(18):5917-5922. doi: 10.1158/1078-0432.CCR-08-2217. [PubMed] [Cross Ref]
24. Vadhan-Raj S, Weber D, Wang M, Giral S, Alexanian R, Thomas S, et al. Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: results of a phase 1/2 study. *Blood*. 2007;110(11):357a.
25. Polasa K, Raghuram TC, Krishna TP, Krishnaswamy K. Effect of turmeric on urinary mutagens in smokers. *Mutagenesis*. 1992;7(2):107-109. doi: 10.1093/mutage/7.2.107. [PubMed] [Cross Ref]
26. Kuttan R, Sudheeran PC, Joseph CD. Turmeric and curcumin as topical agents in cancer therapy. *Tumori*. 1987;73(1):29-31. [PubMed]
27. Hastak K, Lubri N, Jakhi SD, More C, John A, Ghaisas SD, et al. Effect of turmeric oil and turmeric oleoresin on cytogenetic damage in patients suffering from oral submucous fibrosis. *Cancer Lett*. 1997;116(2):265-269. doi: 10.1016/S0304-3835(97)00205-X. [PubMed] [Cross Ref]
28. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Res*. 2001;21(4B):2895-2900. [PubMed]
29. Chainani-Wu N, Silverman S, Jr, Reingold A, Bostrom A, Mc Culloch C, Lozada-Nur F, et al. A randomized,





- placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. *Phytomedicine*. 2007;14(7-8):437–446. doi: 10.1016/j.phymed.2007.05.003. [PubMed] [Cross Ref]
30. Rai B, Kaur J, Jacobs R, Singh J. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. *J Oral Sci*. 2010;52(2):251–256. doi: 10.2334/josnusd.52.251. [PubMed] [Cross Ref]
31. Kim SG, Veena MS, Basak SK, Han E, Tajima T, Gjertson DW, et al. Curcumin treatment suppresses IKKbeta kinase activity of salivary cells of patients with head and neck cancer: a pilot study. *Clin Cancer Res*. 2011;17(18):5953–5961. doi: 10.1158/1078-0432.CCR-11-1272. [PMC free article] [PubMed] [Cross Ref]
32. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. *Dig Dis Sci*. 2005;50(11):2191–2193. doi: 10.1007/s10620-005-3032-8. [PubMed] [Cross Ref]
33. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. *Clin Gastroenterol Hepatol*. 2006;4(12):1502–1506. doi: 10.1016/j.cgh.2006.08.008. [PubMed] [Cross Ref]
34. Lahiff C, Moss AC. Curcumin for clinical and endoscopic remission in ulcerative colitis. *Inflamm Bowel Dis*. 2011;17(7):E66. doi: 10.1002/ibd.21710. [PubMed] [Cross Ref]
35. Epstein J, Docena G, MacDonald TT, Sanderson IR. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. *Br J Nutr*. 2010;103(6):824–832. doi: 10.1017/S0007114509992510. [PubMed] [Cross Ref]
36. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomatology in otherwise healthy adults: a pilot study. *J Altern Complement Med*. 2004;10(6):1015–1018. doi: 10.1089/acm.2004.10.1015. [PubMed] [Cross Ref]
37. Shimouchi A, Nose K, Takaoka M, Hayashi H, Kondo T. Effect of dietary turmeric on breath hydrogen. *Dig Dis Sci*. 2009;54(8):1725–1729. doi: 10.1007/s10620-008-0550-1. [PubMed] [Cross Ref]
38. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane) *Indian J Med Res*. 1980;71:632–634. [PubMed]
39. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. *Phytother Res*. 2012;26(11):1719–25. doi: 10.1002/ptr.4639. [PubMed]
40. Belcaro G, Cesarone MR, Dugali M, Pellegrini L, Ledda A, Grossi MG, et al. Product-evaluation registry of Meriva(R), a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. *Painmanagement*. 2010;52(2 Suppl 1):55–62. [PubMed]
41. Belcaro G, Cesarone MR, Dugali M, Pellegrini L, Ledda A, Grossi MG, et al. Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. *Altern Med Rev*. 2010;15(4):337–344. [PubMed]
42. Lal B, Kapoor AK, Asthana OP, Agrawal PK, Prasad R, Kumar P, et al. Efficacy of curcumin in the management of chronic anterior uveitis. *Phytother Res*. 1999;13(4):318–322. doi: 10.1002/(SICI)1099-1573(199906)13:4<318::AID-PTR445>3.0.CO;2-7. [PubMed] [Cross Ref]
43. Allegri P, Mastromarino A, Neri P. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. *Clin Ophthalmol*. 2010;4:1201–1206. [PMC free article] [PubMed]
44. Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. *Int J Clin Pharmacol Ther Toxicol*. 1986;24(12):651–654. [PubMed]
45. Kositchaiwat C, Kositchaiwat S, Havanondha J. Curcuma longa Linn. in the treatment of gastric ulcer compared to liquid antacid: a controlled clinical trial. *J Med Assoc Thai*. 1993;76(11):601–605. [PubMed]
46. Prucksunand C, Indrasukhsri B, Leethochawalit M, Hungsreungs K. Phase II clinical trial on effect of the long turmeric (*Curcuma longa* Linn) on healing of peptic ulcer. *Southeast Asian J Trop Med Public Health*. 2001;32(1):208–215. [PubMed]
47. Di Mario F, Cavallaro LG, Nouvenne A, Stefani N, Cavestro GM, Iori V, et al. A curcumin-based 1-week triple therapy for eradication of *Helicobacter pylori* infection: something to learn from failure? *Helicobacter*. 2007;12(3):238–243. doi: 10.1111/j.1523-5378.2007.00497.x. [PubMed] [Cross Ref]
48. Koosirirat C, Limpisarn S, Changsom D, Chawansuntati K, Wipasa J. Investigation of the anti-inflammatory effect of Curcuma longa in *Helicobacter pylori*-infected patients. *Int Immunopharmacol*. 2010;10(7):815–818. doi: 10.1016/j.intimp.2010.04.021. [PubMed] [Cross Ref]
49. Lal B, Kapoor AK, Agrawal PK, Asthana OP, Srimal RC. Role of curcumin in idiopathic inflammatory orbital pseudotumors. *Phytother Res*. 2000;14(6):443–447. doi: 10.1002/1099-1573(200009)14:6<443::AID-PTR619>3.0.CO;2-V. [PubMed] [Cross Ref]
50. Asawanonda P, Klahan SO. Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study. *Photomed Laser Surg*. 2010;28(5):679–684. doi: 10.1089/pho.2009.2637. [PubMed] [Cross Ref]
51. Heng MC, Song MK, Harker J, Heng MK. Drug-induced suppression of phosphotyrosine kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. *Br J Dermatol*. 2000;143(5):937–949. doi: 10.1046/j.1365-2133.2000.03767.x. [PubMed] [Cross Ref]
52. Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. *J Am Acad Dermatol*. 2008;58(4):625–631. doi: 10.1016/j.jaad.2007.12.035. [PMC free article] [PubMed] [Cross Ref]
53. Burns J, Joseph PD, Rose KJ, Ryan MM, Ouvrier RA. Effect of oral curcumin on Dejerine-Sottas disease. *Pediatr Neurol*. 2009;41(4):305–308. doi: 10.1016/j.pediatrneurol.2009.04.030. [PubMed] [Cross Ref]
54. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. *Curr Alzheimer Res*. 2005;2(2):131–136. doi: 10.2174/1567205053585882. [PMC free article] [PubMed] [Cross Ref]
55. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. *J Clin Psychopharmacol*. 2008;28(1):110–113. doi: 10.1097/jcp.0b013e318160882c. [PubMed] [Cross Ref]
56. Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB, et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. *Acta Med Indones*. 2008;40(4):201–210. [PubMed]
57. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. *Indian J Physiol Pharmacol*. 1992;36(4):273–275. [PubMed]
58. Srinivasan M. Effect of curcumin on blood sugar as seen in a diabetic subject. *Indian J Med Sci*. 1972;26(4):269–270. [PubMed]
59. Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. *Drugs R D*. 2008;9(4):243–250. doi: 10.2165/00126839-200809040-00004. [PubMed] [Cross Ref]
60. Wickenberg J, Ingemansson SL, Hlebowitcz J. Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. *Nutr J*. 2010;9:43. doi: 10.1186/1475-2891-9-43. [PMC free article] [PubMed] [Cross Ref]
61. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. *Diabetes Care*. 2012;35(11):2121–7. doi: 10.2337/dc12-0116. [PMC free article] [PubMed] [Cross Ref]
62. Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. *Scand J Urol Nephrol*. 2011;45(5):365–370. doi: 10.3109/00365599.2011.585622. [PubMed] [Cross Ref]
63. Appendino G, Belcaro G, Cornelli U, Luzzi R, Togni S, Dugali M, et al. Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study. *Painmanagement*. 2011;53(3 Suppl 1):43–49. [PubMed]
64. Khajehdehi P, Zanjaninejad B, Afkari E, Nazarinia M, Azad F, Malekmakan L, et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. *J Ren Nutr*. 2012;22(1):50–57. doi: 10.1053/j.jrn.2011.03.002. [PubMed] [Cross Ref]
65. Shoskes D, Lapiere C, Cruz-Correa M, Muruve N, Rosario R, Fromkin B, et al. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. *Transplantation*. 2005;80(11):1556–1559. doi: 10.1097/01.tp.0000183290.64309.21. [PubMed] [Cross Ref]
66. James JS. Curcumin: clinical trial finds no antiviral effect. *AIDS Treat News*. 1996;(no 242):1–2. [PubMed]
67. Kalpravidh RW, Siritanaratkul N, Insain P, Charoen-sakdi R, Panichkul N, Hatairaktham S, et al. Improvement in oxidative stress and antioxidant parameters in beta-thalassemia/Hb E patients treated with curcuminoids. *Clin Biochem*. 2010;43(4–5):424–429. doi: 10.1016/j.clinbiochem.2009.10.057. [PubMed] [Cross Ref]
68. Niederau C, Gopfert E. The effect of chelidonium- and turmeric root extract on upper abdominal pain due to functional disorders of the biliary system. Results from a placebo-controlled double-blind study. *Med Klin (Munich)*. 1999;94(8):425–430. doi: 10.1007/BF03044726. [PubMed] [Cross Ref]
69. Rasyid A, Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. *Aliment Pharmacol Ther*. 1999;13(2):245–249. doi: 10.1046/j.1365-2036.1999.00464.x. [PubMed] [Cross Ref]
70. Zuccotti GV, Trabattoni D, Morelli M, Borgonovo S, Schneider L, Clerici M. Immune modulation by lactoferrin and curcumin in children with recurrent respiratory infections. *J Biol Regul Homeost Agents*. 2009;23(2):119–123. [PubMed]
71. Adhvariyu MR, Reddy N, Vakharia BC. Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach. *World J Gastroenterol*. 2008;14(30):4753–4762. doi: 10.3748/wjg.14.4753. [PMC free article] [PubMed] [Cross Ref]
72. Biswas J, Sinha D, Mukherjee S, Roy S, Siddiqi M, Roy M. Curcumin protects DNA damage in a chronically arsenic-exposed population of West Bengal. *Hum Exp Toxicol*. 2010;29(6):513–524. doi: 10.1177/0960327109359020. [PubMed] [Cross Ref]
73. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, et al. Innovative preparation of curcumin for improved oral bioavailability. *Biol Pharm Bull*. 2011;34(5):660–665. doi: 10.1248/bpb.34.660. [PubMed] [Cross Ref]
74. Cai T, Mazzoli S, Bechi A, Addonizio P, Mondaini N, Pagliai RC, et al. Serenoa repens associated with 5-alpha-dihydro (ProstaMEV) and curcumin and quercetin (Flog-MEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. *Int J Antimicrob Agents*. 2009;33(6):549–553. doi: 10.1016/j.ijantimicag.2008.11.012. [PubMed] [Cross Ref]
75. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm*. 2007;4(6):807–818. doi: 10.1021/mp700113r. [PubMed] [Cross Ref]
76. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med*. 1998;64(4):353–356. doi: 10.1055/s-2006-957450. [PubMed] [Cross Ref]
77. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. *J Agric Food Chem*. 2010;58(4):2095–2099. doi: 10.1021/jf9024807. [PubMed] [Cross Ref]
78. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, et al. Comparative absorption of a standardized curcuminoid mixture and its licitoin formulation. *J Nat Prod*. 2011;74(4):664–669. doi: 10.1021/np1007262. [PubMed] [Cross Ref]
79. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcuma), a novel bioenhanced preparation of curcumin. *Indian J Pharm Sci*. 2008;70(4):445–449. doi: 10.4103/0250-474X.44591. [PMC free article] [PubMed] [Cross Ref]
80. Disilverino LA, Joseph E, Zhao S, Joshua B. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. *Nutr J*. 2012;11(1):79. doi: 10.1186/1475-2891-11-79. [PMC free article] [PubMed] [Cross Ref]
81. Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it? *Mol Nutr Food Res*. 2008;52(9):1010–1030. doi: 10.1002/mnfr.200700354. [PubMed] [Cross Ref]
82. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. *Cancer Metastasis Rev*. 2010;29(3):405–434. doi: 10.1007/s10555-010-9235-2. [PMC free article] [PubMed] [Cross Ref]
83. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. *HPB (Oxford)*. 2008;10(1):58–62. doi: 10.1080/13651820701883148. [PMC free article] [PubMed] [Cross Ref]
84. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. *Clin Lymphoma Myeloma*. 2005;6(2):102–114. doi: 10.3816/CLM.2005.n.036. [PubMed] [Cross Ref]
85. Scully C, Beyli M, Ferreira MC, Ficarra G, Gill Y, Griffiths M, et al. Update on oral lichen planus: etiopathogenesis and management. *Crit Rev Oral Biol Med*. 1998;9(1):86–122. doi: 10.1177/10454411980090010501. [PubMed] [Cross Ref]
86. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. *Clin Cancer*





Res. 2009;15(2):425–430. doi: 10.1158/1078-0432.CCR-08-0149. [PubMed] [Cross Ref]

87. Megraud F, Brassens-Rabbe MP, Denis F, Belbourni A, Hoa DQ. Seroepidemiology of *Campylobacter pylori* infection in various populations. *J Clin Microbiol*. 1989;27(8):1870–1873. [PMC free article] [PubMed]

88. Birch-Hirschfeld A. Zur diagnostik und pathologic der orbital tumoren. *Ber Dtsch Ophthalmol Ges*. 1905;32:127–135.

89. Orcutt JC, Garner A, Henk JM, Wright JE. Treatment of idiopathic inflammatory orbital pseudotumours by radiotherapy. *Br J Ophthalmol*. 1983;67(9):570–574. doi: 10.1136/bjo.67.9.570. [PMC free article] [PubMed] [Cross Ref]

90. Schallreuter KU, Wood JM, Pittelkow MR, Buttner G, Swanson N, Korner C, et al. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. *Arch Dermatol Res*. 1996;288(1):14–18. doi: 10.1007/BF02505037. [PubMed] [Cross Ref]

91. Arca E, Tastan HB, Erbil AH, Sezer E, Koc E, Kurumlu Z. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. *J Dermatol*. 2006;33(5):338–343. doi: 10.1111/j.1346-8138.2006.00079.x. [PubMed] [Cross Ref]

92. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA*. 2006;296(14):1735–1741. doi: 10.1001/jama.296.14.1735. [PubMed] [Cross Ref]

93. Reddy S, Aggarwal BB. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. *FEBS Lett*. 1994;341(1):19–22. doi: 10.1016/0014-5793(94)80232-7. [PubMed] [Cross Ref]

94. Mattson MP, Rydel RE. Alzheimer's disease. Amyloid α -toxic transducers. *Nature*. 1996;382(6593):674–675. doi: 10.1038/382674a0. [PubMed] [Cross Ref]

95. Goyal A, Petersen JL, Mahaffey KW. The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes. *Curr Cardiol Rep*. 2004;6(4):300–307. doi: 10.1007/s11886-004-0080-1. [PubMed] [Cross Ref]

96. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med*. 1999;340(2):115–126. doi: 10.1056/NEJM199901143400207. [PubMed] [Cross Ref]

Green Tea

Baladia E, Basulto J, Manera M, Martinez R, Calbet D. Effect of green tea or green tea extract consumption on body weight and body composition: systematic review and meta-analysis. *Nutr Hosp*. 2014; 29(3):479–90.

Belza A, Toubro S, Astrup A. The effect of caffeine, green tea and tyrosine on thermogenesis and energy intake. *Eur J Clin Nutr*. 2007; [Epub ahead of print].

Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. *Cancer Res*. 2006;66(2):1234–40.

Borrelli F, Capasso R, Russo A, Ernst E. Systematic review: green tea and gastrointestinal cancer risk. *Aliment Pharmacol Ther*. Mar 1, 2004;19(5):497–510.

Boschmann M, Thielecke F. The effects of epigallocatechin-3-gallate on thermogenesis and fat oxidation in obese men: a pilot study. *J Am Coll Nutr*. 2007;26(4):389S–95S.

Brown AL, Lane J, Holyoak C, Nicol B, Mayes AE, Dadd T. Health effects of green tea catechins in overweight and obese men: a randomised controlled cross-over trial. *Br J Nutr*. 2011 Jun 7;110. [Epub ahead of print].

Cooper R, Morre DJ, Morre DM. Medicinal benefits of green tea: Part I. Review of noncancer health benefits. *J Altern Complement Med*. 2005;11(3):521–8.

Diepvens K, Westerterp KK, Westerterp-Plantenga MS. Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin and green tea. *Am J Physiol Regul Integr Comp Physiol*. 2007;292(1):R77–85.

Fritz H, Seely D, Kennedy DA, Fernandes R, Cooley K, Ferguson D. Green tea and lung cancer: a systemic review. *Integr Cancer Ther*. 2013;12(1):7–24.

Fujita H, Yamagami T. Antihypercholesterolemic effect of Chinese black tea extract in human subjects with borderline hypercholesterolemia. *Nutr Res*. 2008;28(7):450–6.

Fukino Y, Ikeda A, Maruyama K, Aoki N, Okubo T, Iso H. Randomized controlled trial for an effect of green tea extract powder supplementation on glucose abnormalities. *Eur J Clin Nutr*. 2007; [Epub ahead of print].

Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon(R) E in the treatment of external genital warts. *J Eur Acad Dermatol Venereol*. 2007;21(10):1404–12.

Hartley L, Flowers N, Holmes J, et al. Green and black tea for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2013;6(1):CD009934.

Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. [review]. *Am J*

Health Syst Pharm. 2000 Jul 1;57(13):1221–7.

Hsu CH, Liao YL, Lin SC, Tsai TH, Huang CJ, Chou P. Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. *Altern Med Rev*. 2011 Jun;16(2):157–63.

Inoue M, Tajima K, Mizutani M, et al. Regular consumption of green tea and the risk of breast cancer recurrence: follow-up study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), Japan. *Cancer Lett*. 2001;167(2):175–82.

Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. *Int J Cancer* Jan 1, 2004;108(1):130–5.

Jiao H, Hu G, Gu D, Ni X. Having a promising efficacy on type II diabetes, it's definitely a green tea time. *Curr Med Chem*. 2015;22(1):70–9.

Jin X, Zheng RH, Li YM. Green tea consumption and liver disease: a systematic review. *Liver Int*. 2008;28(7):990–6.

Katiyar SK, Ahmad N, Mukhtar H. Green tea and skin. *Arch Dermatol*. 2000;136(8):989–94.

Kato A, Minoshima Y, Yamamoto J, Adachi I, Watson AA, Nash RJ. Protective effects of dietary chamomile tea on diabetic complications. *J Agric Food Chem*. 2008;56(17):8206–11.

Khalesi S, Sun J, Buys N, et al. Green tea catechins and blood pressure: a systematic review and meta-analysis of randomised controlled trials. *Eur J Nutr*. 2014;53(6):1299–311.

Kimura K, Ozeki M, Juneja LR, Ohira H. L-Theanine reduces psychological and physiological stress responses. *Biol Psychol*. 2007;74(1):39–45.

Koo SJ, Nah SK. Green tea as an inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. *J Nutr Biochem*. 2007;18(3):179–83.

Kovacs EM, Lejeune MP, Nijis J, Westerterp-Plantenga MS. Effects of green tea on weight maintenance after body-weight loss. *Br J Nutr*. Mar 1, 2004;91(3):431–7.

Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, Tsubono Y, Tsuji I. Green tea consumption and mortality due to cardiovascular disease, cancer and all causes in Japan: the Ohsaki study. *JAMA*. 2006;296(10):1255–65.

Lee W, Min WK, Chun S, Lee YW, Park H, Lee do H, Lee YK, Son JE. Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers. *Clin Biochem*. Jan 1, 2005;38(1):84–87.

Liu K, Zhou R, Wang B, et al. Effect of green tea on glucose control and insulin sensitivity: a meta-analysis of 17 randomized controlled trials. *Am J Clin Nutr*. 2013;98(2):340–8.

Low Dog T, Riley D, Carter T. Traditional and alternative therapies for breast cancer. *Alt Ther*. 2001;7(3):36–47.

McKenna DJ, Hughes K, Jones K. Green tea monograph. *Herb*. 2000;6(3):61–84.

Miura Y, Chiba T, Tomita I, et al. Tea catechins prevent the development of atherosclerosis in apolipoprotein E-deficient mice. *J Nutr*. 2001;131(1):27–32.

Nagao T, Hase T, Tokimitsu I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. *Obesity (Silver Spring)*. 2007;15(6):1473–83.

Narotzki B, Reznick AZ, Aizenbud D, Levy Y. Green tea: a promising natural product in oral health. *Arch Oral Biol*. 2012; 57(5):429–35.

Noguchi-Shinohara M, Yuki S, Dohmoto C, et al. Consumption of green tea, but not black tea or coffee, is associated with reduced risk of cognitive decline. *PLoS One*. 2014; 9(5):e96013.

Pazyar N, Feily A, Kazerooni A. Green tea in dermatology. *Skinmed*. 2012;10(6):352–5.

Peters U, Poole C, Arab L. Does tea affect cardiovascular disease? A meta-analysis. *Am J Epidemiol*. 2001;154(6):495–503.

Pianetti S, Guo S, Kavanagh KT, Sonenshein GE. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. *Cancer Res*. 2002;62(3):652–5.

Rakel. *Integrative Medicine*. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2012.

Rowe CA, Nantz MP, Bukowski JF, Percival SS. Specific formulation of *Camellia sinensis* prevents cold and flu symptoms and enhances gammadelta T cell function: a randomized, double-blind, placebo-controlled study. *J Am Coll Nutr*. 2007;26(5):445–52.

Ryu OH, Lee J, Lee KW, et al. Effects of green tea consumption on inflammation, insulin resistance and pulse wave velocity in type 2 diabetes patients. *Diabetes Res Clin Pract*. 2006;71(3):356–8.

Sano T, Sasako M. Green tea and gastric cancer. *N Engl J Med*. 2001;344(9):675–6.

Sasazuki S, Kodama H, Yoshimasu K et al. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. *Ann Epidemiol*. 2000;10:401–8.

Setiawan VW, Zhang ZF, Yu GP, et al. Protective effect of green tea on the risks of chronic gastritis and stomach cancer. *Int J Cancer*. 2001;92(4):600–4.

Shankar S, Ganapathy S, Hingorani SR, Srivastava RK.

EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. *Front Biosci*. 2008;13:440–52.

Steptoe A, Gibson EL, Vuononvirta R, Hamer M, Wardle J, Rycroft JA, Martin JF, Erusalimsky JD. The effects of chronic tea intake on platelet activation and inflammation: a double-blind placebo controlled trial. *Atherosclerosis*. 2007;193(2):277–82.

Suzuki Y, Tsubono Y, Nakaya N, Suzuki Y, Koizumi Y, Tsuji I. Green tea and the risk of breast cancer: pooled analysis of two prospective studies in Japan. *Br J Cancer*. Apr 5, 2004;90(7):1361–3.

Thatte U, Bagadey S, Dahanukar S. Modulation of programmed cell death by medicinal plants. [Review]. *Cell Mol Biol*. 2000;46(1):199–214.

Thavanesan N. The putative effects of green tea on body fat: an evaluation of the evidence and a review of the potential mechanisms. *Br J Nutr*. 2011 Aug 3;113. [Epub ahead of print].

Trudel D, Labbe DP, Bairati I, Fradet V, Bazinet L, Tetu B. Green tea for ovarian cancer prevention and treatment: a systemic review of the in vitro, in vivo and epidemiological studies. *Gynecol Oncol*. 2012;126(3):491–8.

Tsubono Y, Nishino Y, Komatsu S, et al. Green tea and the risk of gastric cancer in Japan. *N Engl J Med*. 2001;344(9):632–6.

Vinson JA, Teufel K, Wu N. Green and black teas inhibit atherosclerosis by lipid, antioxidant, and fibrinolytic mechanisms. *J Agric Food Chem*. 2004;52(11):3661–5.

Wargovich MJ, Woods C, Hollis DM, Zande ME. Herbs, cancer prevention and health. [Review]. *J Nutr*. 2001;131(11 Suppl):3034S–36S.

Westerterp-Plantenga MS, Lejeune MP, Kovacs EM. Body weight and weight maintenance in relation to habitual caffeine intake and green tea. *Obes Res*. Jul 2005;13(7):1195–204.

Wu AH, Butler LM. Green tea and breast cancer. *Mol Nutr Food Res*. 2011 Jun;55(6):921–30.

Yang G, Shu XO, Li H, Chow WH, Ji BT, Zhang X, Gao YT, Zheng W. Prospective cohort study of green tea consumption and colorectal cancer risk in women. *Cancer Epidemiol Biomarkers Prev*. 2007;16(6):1219–23.

Yang G, Zheng W, Xiang YB, Gao J, Li HL, Zhang X, Gao YT, Shu XO. Green tea consumption and colorectal cancer risk: a report from the Shanghai Men's Health Study. *Carcinogenesis*. 2011 Sep 8. [Epub ahead of print].

Yuan JM. Cancer prevention by green tea: evidence from epidemiologic studies. *Am J Clin Nutr*. 2013; 98(6 Suppl):1676S–81S.

Yuan JM. Green tea and prevention of esophageal and lung cancers. *Mol Nutr Food Res*. 2011 Jun;55(6):886–904.

Zhang M, Lee AH, Binns CW, Xie X. Green tea consumption enhances survival of epithelial ovarian cancer. *Int J Cancer*. Nov 10, 2004;112(3):465–9.

Zheng J, Yang B, Huang T, Yu Y, Yang J, Li D. Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. *Nutr Cancer*. 2011;63(5):663–72. Epub 2011 Jun 11.

Zheng XX, Xu YL, Li SH, Liu XX, Hui R, Huang XH. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. *Am J Clin Nutr*. 2011;94(2):601–10.

Zheng XX, Xu YL, Li SH, Hui R, Wu YJ, Huang XH. Effects of green tea catechins with or without caffeine on glycemic control in adults: a meta-analysis of randomized controlled trials. *Am J Clin Nutr*. 2013;97(4):750–62.

Zhou B, Yang L, Wang L, Shi Y, Zhu H, Tang N, Wang B. The association of tea consumption with ovarian cancer risk: a meta-analysis. *Am J Obstet Gynecol*. 2007;197(6):594.e1–6.

Resveratrol:

Baur JA1, Sinclair DA. Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA. Therapeutic potential of resveratrol: the in vivo evidence. *Nat Rev Drug Discov*. 2006 Jun;5(6):493–506. Epub 2006 May 26.

Sun AY1, Wang Q, Simonyi A, Sun GY. Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65212, USA. suna@health.missouri.edu. Resveratrol as a therapeutic agent for neurodegenerative diseases. *Mol Neurobiol*. 2010 Jun;41(2–3):375–83. doi: 10.1007/s12035-010-8111-y. Epub 2010 Mar 21.

Langley E, et al., Human SIRT2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. *EMBO J*. 21 (2002) 2383–2396.

Howitz K, T, et al., Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature* 425 (2003) 191–196.

Wood J, G., et al., Sirtuin activators mimic calorie restriction and delay ageing in metazoans. *Nature* 430 (2004) 686–689.

Araki, T., Sasaki, Y., Milbrandt, J., Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. *Science* 305 (2004) 1010–1013.

Baur, J. A., et al., Resveratrol improves health and sur-



- vival of mice on a high-calorie diet. *Nature* Vol. 444 (2006) 337-342.
- Walle, T., et al., High absorption but very low bioavailability of oral resveratrol in humans. *Drug Metab. Dispos.* 32 (2004) 1377-1382.
- Mertens-Talcott, S. U., Percival, S. S., Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. *Cancer Lett.* 218 (2005) 141-152.
- Pervaiz, S., Resveratrol. From grapevines to mammalian biology. *FASEB J.* 17 (2003) 1975-1985.
- Crowell, J. A., et al., Resveratrol-associated renal toxicity. *Toxicol. Sciences* 82 (2004) 614-619.
- Sui DM1, Xie Q2, Yi WJ2, Gupta S3, Yu XY2, Li JB2, Wang J2, Wang JF2, Deng XM2. Resveratrol Protects against Sepsis-Associated Encephalopathy and Inhibits the NLRP3/IL-1 β Axis in Microglia. 1Department of Anesthesiology and Intensive Care, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai 200433, China; Department of Anesthesiology, Chengdu Military General Hospital, 270 Tianhui Road, Chengdu 610083, China. 2Department of Anesthesiology and Intensive Care, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai 200433, China. 3The Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, 209 Victoria Street, Toronto, ON, Canada M5B 1T8; Department of Surgery, St. Michael's Hospital, University of Toronto, 30 Bond Street, Toronto, ON, Canada M5B 1W8. *Mediators Inflamm.* 2016;2016:1045657. doi: 10.1155/2016/1045657. Epub 2016 Jan 26.
- Chang YP1, Ka SM, Hsu WH, Chen A, Chao LK, Lin CC, Hsieh CC, Chen MC, Chiu HW, Ho CL, Chiu YC, Liu ML, Hua KF. Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy. 1Department of Biotechnology and Animal Science, National Ilan University, Ilan, Taiwan. *n J Cell Physiol.* 2015 Jul;230(7):1567-79. doi: 10.1002/jcp.24903.
- Armour SM1, Baur JA, Hsieh SN, Land-Bracha A, Thomas SM, Sinclair DA. Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. 1Department of Pathology and Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA 02115, USA (Albany NY). 2009 Jun 3;1(6):515-28.
- Sinclair DA. Studying the replicative life span of yeast cells. *Methods Mol Biol.* 2013;1048:49-63. doi: 10.1007/978-1-62703-556-9_5. PMID: 23929097 [PubMed - in process]
- YU Xing1,2, GAO Li-ping1, XIA Tao3 (1.School of Life Science, Anhui Agricultural University, Hefei 230036; 2. Institute of Anhui Geological Research, Hefei 230001; 3. Key Laboratory of Tea Biochemistry and Biotechnology, Ministry of Agriculture, Anhui Agricultural University, Hefei 230036); Change trends of resveratrol and relevant enzymes during the development of grape [J]; *Journal of Anhui Agricultural University*; 2007-04
- CHEN Xiu-xia~1, CHEN You-qiang~1, CHEN Ru-kai~2 (1. Bioengineering College, Fujian Teachers University, Fuzhou 3 of Agriculture, P.R. Fuzhou 350002, China); Advances in the Research of Resveratrol [J]; *Journal of Fujian Forestry Science and Technology*; 2003-04
- Ji Jing-yuan, ZHANG Zhan-peng, ZHANG Bian-ling, XUE Ke, Ji Er-yong, WEI Ya-hui (Key Laboratory of Ministry of Education for Western China Resource Biology and Biotechnology, College of Life Sciences, Northwest University, Xi'an, Shanxi 710069, China); Study on Biological Technology of Resveratrol [J]; *Guizhou Agricultural Sciences*; 2008-04
- Guo Jingnan 1, Liu Chonghuai 1, Pan Xing 1, and Wang Jishuan 2 (1 Zhengzhou Fruit Research Institute, CAAS, Zhengzhou, Henan 450009; 2 Yanshi Agricultural Science and Technology Extension Centre, Yanshi, Henan 471900); Advances in Research on Resveratrol in *Vitis* spp. [J]; *Journal of Fruit Science*; 2002-03
- ZHENG Xian-bo1, 2, 4, Li Xiao-dong2, WU Ben-hong2, WAMH Li-jun2, Li Shao-hua3 (1College of Agronomy and Biotechnology, China Agricultural University, Beijing 100093 China; 2Institute of Botany, Chinese Academy of Sciences, Beijing 100093 China; 3Wuhan Botanical Garden, Chinese Academy of Sciences, Wuhan, Hubei 430074 China; 4College of Horticulture, Henan Agricultural University, Zhengzhou, Henan 450002 China); Effects of UV-C irradiation on resveratrol and its glycosides content in leaves and the berries of neighboring clusters of potted Beifeng grape vines (*Vitis thunbergii* \times *Vitis vinifera*) [J]; *Journal of Fruit Science*; 2009-04
- LI Ting1, LI Sheng1, 2, ZHANG Qing-song1, ZHANG Zhen1, LIU Yuan1, WU Yuan-yuan1 (1.College of Life Science and Technology, Gansu Agricultural University, Lanzhou 730070, China; 2. Huitong Biological Technology Company, Lanzhou 730070, China); Comparison of the resveratrol contents in different grape tissues [J]; *Journal of Gansu Agricultural University*; 2009-02
- YU Hua-zhong~1, LI Guo-zhang~1, CAO Yong~1, LIAO Shu-qiao~1, LONG Wei-zhen~2y Engineering, Jishou University, Zhangjiajie 427000, China; 2. The Institute of Zhangjiajie Forestry Science, Zhangjiajie 427000, China); RESEARCH ON THE DRYING METHODS OF RESVERATROL EXTRACTED FROM POLYGONUM CUSPIDATUM [J]; *Journal of Chemical Industry of Forest Products* (Bimonthly); 2005-01
- Shan Huijun Zhang Mingwei Zhang Ruifen Chi Jianwei Zhang Yan Wei Zhencheng (Guangdong Academy of Agricultural Sciences); Research on Extraction Technology of Resveratrol from Roots of Peanut [J]; *Transactions of the Chinese Society for Agricultural Machinery*; 2008-02
- LIU Jin-bao, DU Zhong-jun, ZHAI Heng (College of Horticultural, Shandong Agricultural University, Shandong, Tai'an 271018); The Main Polyphenolics in Grape Berry and Their Influencing Factors [J]; *Sino-overseas Grapevine & Wine*; 2003-02

... immer aktuell auf
www.crystalswiss.com

